Eukaryotic mRNA Processing: Exons, Introns & Splicing

Alternative splicing is a regulated RNA processing mechanism that enables a single gene to produce multiple protein isoforms by selectively including or excluding different exons during mRNA maturation, thereby dramatically increasing proteomic diversity beyond what would be possible from the relatively small number of protein-coding genes in the human genome.

Alternative splicing is a eukaryotic RNA processing mechanism that generates multiple protein isoforms from a single pre-mRNA transcript by selectively including or excluding exons or retaining introns, thereby dramatically increasing proteomic diversity; this process is regulated by cis-acting regulatory elements (exonic splicing enhancers/silencers and intronic splicing enhancers/silencers) that interact with the spliceosome complex, and encompasses various types including exon skipping, intron retention, alternative splice site selection, and alternative promoter usage.

Alternative splicing allows a single gene to produce multiple different proteins by including or excluding different combinations of exons. This process is regulated by the spliceosome and can produce proteins with different functions, localization, or properties from the same gene. Alternative splicing significantly increases the complexity of the proteome (total set of proteins) in eukaryotic cells, allowing for greater functional diversity from a limited number of genes.

Alternative splicing is the process by which a single gene can produce multiple different proteins. After transcription produces the primary mRNA transcript, introns (non-coding regions) are removed and exons (coding regions) are spliced together. Different combinations of exons can be included or excluded, or exons can be spliced at different junctions, producing mature mRNAs that encode different proteins. This mechanism allows one gene to generate multiple functional proteins with potentially different properties, significantly increasing proteomic diversity.

The spliceosome is a complex molecular machine composed of small nuclear RNAs (snRNAs) and proteins that removes introns from pre-mRNA transcripts. U1 snRNP binds to the 5' splice site, while U2 binds to the branch point. The U4/U5/U6 tri-snRNP complex facilitates the actual splicing reaction through two steps: branching and exon ligation. Alternative splicing allows one gene to produce multiple protein isoforms, dramatically increasing proteomic diversity. The human genome contains approximately 20,000 protein-coding genes but produces 75,000-500,000 distinct proteins. Different cell types express different regulatory proteins and small nuclear RNAs that control splicing patterns. Chromatin structure also varies between cell types, controlling which genes can be transcribed. This explains how cells with identical DNA can develop into vastly different tissues—white blood cells versus stomach lining cells—demonstrating that DNA is not destiny but rather part of a complex regulatory system.

The poly-A tail serves as a timer for mRNA stability. Over time, the poly-A tail is shortened by deadenylation. When the tail becomes sufficiently short, poly-A binding proteins fall off, and decapping proteins remove the 5' cap. Once both modifications are removed, the mRNA is rapidly degraded by exonucleases in the cytoplasm. This post-transcriptional regulation determines the lifetime of the mRNA and thus the amount of protein that can be produced from it. The poly-A tail does not terminate transcription; transcriptional termination occurs at the terminator sequence, which is transcribed before the poly-A signal.

Both the 5' cap and poly-A tail protect mRNA from degradation but function differently. The 5' cap completely blocks exonucleases starting at the 5' end, preventing immediate breakdown. The poly-A tail delays degradation by providing a protective sequence that exonucleases must traverse before reaching the mRNA body. This controlled degradation is essential because mRNA molecules are temporary structures—genes are expressed only temporarily, and eventual breakdown helps regulate expression levels. Together, these protective mechanisms ensure mRNA stability during translation while maintaining temporal control over gene expression.

mRNA stability determines how long an mRNA persists before degradation, directly controlling protein synthesis levels. The cytoplasm contains numerous nucleases that can degrade unprotected pre-mRNA, making processing essential for survival. Two critical processing events provide protection: 5' capping adds a seven-methylguanine cap shielding the 5' end from exonucleases, while 3' polyadenylation adds a 10-35 nucleotide poly(A) tail protecting the 3' end. The poly(A)-dependent decay pathway is the primary mechanism for degrading wild-type mRNA. It begins with deadenylases shortening the poly(A) tail. Once sufficiently shortened, decapping enzymes remove the 5' cap. With both protective modifications removed, exonucleases gain access to degrade the mRNA from both ends simultaneously, providing temporal control over mRNA lifespan.

The 5' cap and poly-A tail protect mRNA from degradation by exonucleases that degrade RNA molecules. Without these protective structures, mRNA would be rapidly broken down in the cytoplasm. The length of the poly-A tail affects mRNA stability—the longer the tail, the more stable the mRNA molecule. This mechanism allows cells to regulate gene expression by controlling how long different mRNAs persist in the cell.

In the cytoplasm, the eIF4F complex binds the 5' cap, recruiting eIF4G (scaffold), eIF4A (helicase), and eIF3 to bring the 40S ribosomal subunit. eIF4A unwinds secondary structures blocking ribosome movement. Poly(A)-binding proteins bind cooperatively to the poly-A tail, protecting it from degradation. When deadenylases trim the tail, reduced PABP binding affinity exposes mRNA to degradation. DDX6 proteins coordinate signals between the 5' cap and 3' tail. Two main degradation pathways exist: 5' to 3' via DCP2 decapping and XRN1 exonuclease, and 3' to 5' via the exosome complex with DCPS decapping. These pathways can be distinguished by their degradation products.

Alternative splicing defects cause diseases like spinal muscular atrophy, a devastating childhood condition causing progressive muscle wasting. Research showed defective splicing prevents production of functional survival motor neuron protein. A drug developed by Adrián Krainer corrects this splicing error. Treated children survived beyond the typical 10-month mortality point, achieved motor milestones like sitting and walking, and some now walk independently. This demonstrates how understanding basic molecular mechanisms enables targeted therapies, proving that investment in fundamental research yields transformative medical applications.

Spinal muscular atrophy (SMA) is a devastating genetic disease caused by mutations that disrupt normal splicing of the SMN2 gene. Children with untreated SMA typically die by 10 months of age because their motor neurons cannot properly innervate respiratory muscles. A drug developed by researcher Adrián Kiner (now in New York) corrects the splicing error, allowing the SMN2 gene to produce functional protein. Clinical trials showed remarkable results: children who would have died now survive, walk, and attend school. This represents a direct application of basic research on alternative splicing to developing life-saving therapies.

The central dogma describes genetic information flow: DNA to RNA to protein. Alternative splicing amplifies genetic information by joining different combinations of exons from a single gene transcript, creating multiple protein variants. On average, one gene produces about 10 different mRNA transcripts. Splicing errors are implicated in approximately 13% of human diseases. Spinal Muscular Atrophy (SMA) is caused by mutations in the SMN1 gene, while the SMN2 gene produces a mostly non-functional protein. The goal of treatment is to shift splicing in SMN2 to produce more functional protein.

Mutations that alter splicing patterns are responsible for approximately 20% of human genetic diseases; these mutations can occur in splicing enhancer/silencer sequences, introns, or even coding exons, and can cause diseases such as spinal muscular atrophy (due to reduced SMN protein production), dren (where a nonsense mutation acts as a splicing silencer), and frontal temporal dementia (from altered TAU protein isoform ratios), highlighting the critical importance of proper splicing regulation in human health.